SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma

• A. Rueda Domínguez ^[1] ; J. Alfaro Lizaso ^[7] ; L. de la Cruz Merino ^[2] ; J. Gumá i Padró ^[8] ; C. Quero Blanco ^[9] ; J. Gómez Codina ^[10] ; M. Llanos Muñoz ^[3] ; N. Martinez Banaclocha ^[4] ; D. Rodriguez Abreu ^[5] ; M. Provencio Pulla ^[6]
  1. [1] Hospital Costa Del Sol

     Hospital Costa Del Sol

     Marbella, España

     
  2. [2] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  3. [3] Hospital Universitario de Canarias

     Hospital Universitario de Canarias

     San Cristóbal de La Laguna, España

     
  4. [4] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  5. [5] Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias

     Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias

     Gran Canaria, España

     
  6. [6] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  7. [7] Instituto Oncológico de Guipúzcoa
  8. [8] Hospital Universitari de Sant Joan de Reus
  9. [9] Complejo Hospitalario Regional y Virgen de la Victoria
  10. [10] Hospital Universitari i Politècnic la Fe

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 17, Nº. 12, 2015, págs. 1005-1013
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.